Abstract
The novel satiety factor nesfatin-1 and its precursor NUCB2 are the neuropeptides widely expressed in the central nervous system. Nesfatin-1/NUCB2 is also localized in peripheral tissues and regulates the glucose and energy metabolism on multiple processes. Nesfatin-1 potentiates both insulin release from pancreatic β-cells and insulin action in liver, contributing to energy storage. Furthermore, nesfatin-1/NUCB2 regulates adipocyte differentiation. The polymorphism of the NUCB2 gene is associated with obesity. Thus, nesfatin- 1/NUCB2 plays a role in integrating feeding, glucose homeostasis, and energy storage/expenditure. Dysfunction of expression, secretion and/or action of nesfatin-1/NUCB2 might be involved in the type 2 diabetes, obesity and metabolic syndrome. Nesfatin-1/NUCB2 and its regulatory processes may provide novel targets for treating associated diseases of the metabolic syndrome. Here, we review the by now published studies on nesfatin-1/NUCB2 localization and action in islets and discuss the physiological and pathophysiological roles of the nesfatin-1/NUCB2 in glucose and energy metabolism.
Keywords: Nesfatin-1, insulin release, adipogenesis, feeding.
Current Pharmaceutical Design
Title:Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain
Volume: 19 Issue: 39
Author(s): Masanori Nakata and Toshihiko Yada
Affiliation:
Keywords: Nesfatin-1, insulin release, adipogenesis, feeding.
Abstract: The novel satiety factor nesfatin-1 and its precursor NUCB2 are the neuropeptides widely expressed in the central nervous system. Nesfatin-1/NUCB2 is also localized in peripheral tissues and regulates the glucose and energy metabolism on multiple processes. Nesfatin-1 potentiates both insulin release from pancreatic β-cells and insulin action in liver, contributing to energy storage. Furthermore, nesfatin-1/NUCB2 regulates adipocyte differentiation. The polymorphism of the NUCB2 gene is associated with obesity. Thus, nesfatin- 1/NUCB2 plays a role in integrating feeding, glucose homeostasis, and energy storage/expenditure. Dysfunction of expression, secretion and/or action of nesfatin-1/NUCB2 might be involved in the type 2 diabetes, obesity and metabolic syndrome. Nesfatin-1/NUCB2 and its regulatory processes may provide novel targets for treating associated diseases of the metabolic syndrome. Here, we review the by now published studies on nesfatin-1/NUCB2 localization and action in islets and discuss the physiological and pathophysiological roles of the nesfatin-1/NUCB2 in glucose and energy metabolism.
Export Options
About this article
Cite this article as:
Nakata Masanori and Yada Toshihiko, Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain, Current Pharmaceutical Design 2013; 19 (39) . https://dx.doi.org/10.2174/138161281939131127130112
DOI https://dx.doi.org/10.2174/138161281939131127130112 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Diuretic-Associated Electrolyte Disorders in the Elderly: Risk Factors, Impact, Management and Prevention
Current Drug Safety Impact of Diabetes Mellitus on Radiological Presentation of Pulmonary Tuberculosis in Otherwise Non-Immunocompromised Patients: A Systematic Review
Current Medical Imaging Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Impact of Pre-existing Kidney Dysfunction on Outcomes Following Transcatheter Aortic Valve Replacement
Current Cardiology Reviews Novel Insights into Vascular Repair Mechanisms
Current Pharmaceutical Design Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Elucidating Treatment of Alzheimer's Disease via Different Receptors
Current Topics in Medicinal Chemistry Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design Editorial: Oxidative Stress in Pathophysiological Conditions
Current Vascular Pharmacology Urinary Albumin to Creatinine Ratio as Potential Biomarker for Cerebral Microvascular Disease
Current Neurovascular Research GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews